Adaptive Biotechnologies chief people officer sells $145,845 in stock

In a recent transaction, Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold shares totaling $145,845. The sales occurred on March 5, 2025, and involved two separate transactions. Lo sold 7,085 shares at $6.98 per share and an additional 13,790 shares at $6.99 per share. The stock, currently trading at $7.77, has shown remarkable strength with a 125% return over the past year. According to InvestingPro analysis, ADPT appears slightly undervalued at current levels.

The sales were made to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), as mandated by the company’s equity incentive plan. Following these transactions, Lo holds 332,846 shares directly. Additionally, Lo acquired 99,976 shares of common stock and 150,024 stock options on March 4, 2025, at no cost. These options have an exercise price of $8.12 and are set to vest over a four-year period starting from March 4, 2026. While the company maintains strong liquidity with a current ratio of 2.89, InvestingPro subscribers can access 10 additional key insights about ADPT’s financial health and growth prospects through the comprehensive Pro Research Report.

In other recent news, Adeptus Biotechnologies reported strong fourth-quarter results, surpassing analyst expectations with a revenue of $47.5 million, which marks a 4% increase year-over-year. The company’s adjusted loss per share was $0.23, better than the anticipated $0.25 loss. The Minimal Residual Disease (MRD) business, which accounted for 85% of the fourth-quarter revenue, experienced a 31% year-over-year growth, reaching $40.1 million. However, the Immune Medicine segment saw a 51% decline in revenue, totaling $7.3 million. Looking ahead to 2025, Adeptus projects MRD revenue between $175 million and $185 million, with operating expenses expected to range from $340 million to $350 million and a cash burn of $60 million to $70 million. The company concluded 2024 with $256 million in cash and marketable securities.

In another development, Scotiabank (TSX:BNS) analyst Sung Ji Nam raised Adeptus Biotechnologies’ price target from $10 to $12, maintaining a Sector Outperform rating. This decision reflects optimism about the company’s growth potential, particularly in its MRD business, which is anticipated to achieve adjusted EBITDA profitability in the latter half of 2025. Additionally, the Immune Medicine business is expected to have a reduced risk profile, with revenue from pharmaceutical collaborations likely offsetting research and development investments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.